Latest From ObsEva SA
Public Company Edition: The prior day's after-hours bad news sent biotech stocks lower on 9 August, and IPOs are taking a breather with the NBI down 2.1% over the past month. However, already public companies are raising cash, including Allakos and Ironwood at $350m each.
A second Phase III trial testing relugolix met its primary endpoint, putting Myovant in a tight race with AbbVie to bring the first drug to market for women with uterine fibroids.
Relugolix meets primary and six key secondary endpoints in first Phase III UF study. Magnitude of benefit for primary endpoint does not equal AbbVie’s elagolix, but Myovant thinks it will offer safety, tolerability and convenience advantages.
Drug developers and financiers discuss the biggest challenges delaying novel R&D in diseases effecting only women and how poor awareness of the debilitating symptoms that come with some conditions has led to a lack of emphasis on innovative research.
- Specialty Pharmaceuticals
- Therapeutic Areas
- Gynecological, Urological
- Western Europe
- Parent & Subsidiaries
- ObsEva SA
- Senior Management
Ernest Loumaye, MD, PhD, CEO
Timothy Adams, CFO
Jean-Pierre Gotteland , PhD, CSO
Ben T Tan, VP, Commercial & Bus. Dev.
Elizabeth Garner , MD, CMO
Wim Souverijns, PhD, Chief Commercial Officer
- Contact Info
Phone: (0)22 552 3840
Chemin des Aulx 12
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.